Immunocidin® Demonstrates an Acceptable Safety Profile Following Intravenous Administration in Dogs and Cats with Various Malignancies
Dr. Jeannette Kelly, veterinary oncologist with Veterinary Cancer Care, presented data from a study of multiple IV administrations of Immunocidin® in dogs and cats with various malignancies at the ACVIM Forum last week.
Amplimune® Receives US OMRI Listing for Use in Organic Cattle Production
Amplimune®, our immunotherapeutic for calf scours, has received an Organic Materials Review Institute (OMRI) Listing in the U.S.A. This means that Amplimune can be used in compliance with the USDA National Organic Program.
Iowa State University College of Veterinary Medicine to Conduct a Study with Immunocidin® Equine in Two Types of Cancer
NovaVive's Immunocidin® Equine anticancer immunotherapeutic for horses will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in sarcoids and squamous cell carcinoma.
Settle®, an Antibiotic Alternative for Treating Equine Endometritis, is Now Approved for Sale in New Zealand
NovaVive's immunotherapeutic for the treatment of equine endometritis, Settle®, has been approved for sale to New Zealand veterinarians by the NZ regulator. It was previously approved for sale in the U.S. and Australia.
MCWF Shows Promise in Controlling Mycoplasma in Dairy Cattle
NovaVive's MCWF technology has demonstrated potential to control chronic Mycoplasma bovis (M. bovis) infection in dairy cows. M. bovis causes respiratory disease, ear infection, arthritis, mastitis, abortion and other issues.
NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia
NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.